|
Patent landscape, scope, and claims: |
United States Patent 8,889,159 (GS-7977): Scope, Claim-Construction Levers, and US Patent Landscape
US Patent 8,889,159 claims a specific crystalline form of GS-7977 defined by XRPD peaks, tied to tightly constrained drug loading ranges, excipient selections, and dose-unit specifications for tablet/capsule products, plus a two-stream (intragranular/extragranular) manufacturing process and hepatitis C treatment method claims (including ribavirin combination and interferon-free regimen language).
What matters for freedom-to-operate and generic risk is that the patent is not a “compound claim.” It is a form-and-formulation estate anchored to an XRPD-defined crystalline pattern plus excipient and blend/process structure. Design-around is likely possible only if the applicant can (i) avoid practicing the claimed crystalline form per XRPD, and/or (ii) move outside the claimed drug loading and/or excipient composition windows, and/or (iii) avoid the claimed unit dose and/or the specific intragranular/extragranular blend/compression workflow.
What does US Patent 8,889,159 protect for GS-7977 crystalline form?
Core protection theme: compositions and unit dosage forms containing crystalline GS-7977 characterized by XRPD 2θ-reflections at specified angles, plus excipient systems and dose load targets.
Claim 1 and Claim 16 are the backbone: crystalline GS-7977 + excipient + XRPD pattern + loading/dose
- Claim 1 (composition)
- GS-7977 crystalline with XRPD 2θ-reflections at about 6.1 and 12.7
- Drug loading: about 25% to about 35% w/w crystalline GS-7977
- At least one pharmaceutically acceptable excipient
- Claim 16 (unit dosage form)
- About 400 mg crystalline GS-7977
- XRPD constraint: about 6.1 and 12.7
- At least one pharmaceutically acceptable excipient
Claim 2 and Claim 17 escalate specificity: expanded XRPD peak list
- Claim 2 requires additional XRPD peaks at: 6.1, 8.2, 10.4, 12.7, 17.2, 17.7, 18.0, 18.8, 19.4, 19.8, 20.1, 20.8, 21.8, and 23.3.
- Claim 17 mirrors Claim 2 for the unit dosage form.
Claim-strategy implication:
Even though independent Claim 1/16 only require the “anchor” peaks (6.1 and 12.7), dependent Claims 2 and 17 provide a narrower embodiment. In litigation, the patentee typically seeks to prove the accused product is the same crystalline form that matches the anchor peaks first, then uses expanded peak sets as strengthening evidence (or to capture partially overlapping data).
Which excipients and weight ranges are claimed in US 8,889,159?
The excipient language is broad at the class level (diluent/disintegrant/glidant/lubricant), but becomes operationally narrow when tied to named excipient lists and specific w/w ranges or exemplar formulations.
Dependent claims define excipient categories and named candidates
- Diluent options (Claims 4, 19):
dicalcium phosphate, cellulose, compressible sugars, dibasic calcium phosphate dehydrate, lactose, mannitol, microcrystalline cellulose, starch, tribasic calcium phosphate, combinations.
- Preferred diluent subclass (Claims 5, 20):
mannitol and/or microcrystalline cellulose.
- Disintegrant options (Claims 6, 21):
croscarmellose sodium, crospovidone, microcrystalline cellulose, modified corn starch, povidone, pregelatinized starch, sodium starch glycolate, combinations.
- Preferred disintegrant (Claims 7, 22):
croscarmellose sodium.
- Glidant options (Claims 8, 23):
colloidal silicon dioxide, talc, starch, starch derivatives, combinations.
- Preferred glidant (Claims 9, 24):
colloidal silicon dioxide.
- Lubricant options (Claims 10, 25):
calcium stearate, magnesium stearate, polyethylene glycol, sodium stearyl fumarate, stearic acid, talc, combinations.
- Preferred lubricant (Claims 11, 26):
magnesium stearate.
Composition excipient range claims (Claim 13)
Claim 13 constrains excipient proportions in the composition claim:
- Diluent: about 55% to 65% w/w
- Disintegrant: about 2.5% to 7.5% w/w
- Glidant: about 0.25% to 0.75% w/w
- Lubricant: about 1.25% to 1.75% w/w
This is a key “numerical boundary” that can drive design-around if an ANDA/505(b)(2) formulation targets different excipient ratios.
Exemplar composition formulations (Claims 14 and 15)
- Claim 14 (composition)
- 30% mannitol + 30% microcrystalline cellulose
- 5% croscarmellose sodium
- 0.5% colloidal silicon dioxide
- 1.5% magnesium stearate
- Claim 15 (composition)
- 33% crystalline GS-7977
- 30% mannitol + 30% microcrystalline cellulose
- 5% croscarmellose sodium
- 0.5% colloidal silicon dioxide
- 1.5% magnesium stearate
What unit-dose and dosage-form formats are claimed?
Dose amount and unit form types
- Claim 16 / Claim 17: unit dosage form with about 400 mg crystalline GS-7977.
- Claim 30: unit dosage form is a capsule or a tablet.
Exemplar unit dosage excipient amounts (Claims 28 and 29)
- Claim 28 (ranges in mg):
- Diluent: about 660 mg to 780 mg
- Disintegrant: about 30 mg to 90 mg
- Glidant: about 3 mg to 9 mg
- Lubricant: about 15 mg to 21 mg
- Claim 29 (example set):
- 400 mg GS-7977
- 360 mg mannitol + 356 mg microcrystalline cellulose
- 60 mg croscarmellose sodium
- 6 mg colloidal silicon dioxide
- 18 mg magnesium stearate
Coating agent option (Claims 12 and 27)
- Claim 12: composition further comprising a coating agent.
- Claim 27: unit dosage form further comprising a coating agent.
Design-around note: adding or omitting a coating agent can matter to claim coverage only if coating is required by an asserted dependent claim. Independent Claim 1/16 do not require coating.
What manufacturing process is claimed for tablets in US 8,889,159?
Claim 31 is a process claim tied to a specific formulation workflow:
- Start with unit dosage form of Claim 28
- Steps:
- Blend intragranular composition and extragranular composition
- Compress blended composition to obtain tablet composition
- Optionally coat
Intragranular vs extragranular composition structure
- Intragranular composition includes:
- GS-7977
- first intragranular diluent
- optional second intragranular diluent
- intragranular disintegrant
- intragranular glidant
- intragranular lubricant
- Extragranular composition includes:
- first extragranular diluent
- optional second extragranular diluent
- extragranular glidant
- extragranular disintegrant
- extragranular lubricant
Claim 32 then captures the resulting product:
- Tablet composition comprising about 400 mg of GS-7977 made according to Claim 31.
Litigation lever: process claims can be asserted even when the end formulation is similar, if the patentee can show the accused product is made using the claimed intragranular/extragranular preparation and compression pathway. In practice, proof often depends on manufacturing records, device/feeder schematics, or expert reconstruction from product-specific particle/excipient distribution.
How do the hepatitis C method claims expand the enforcement reach?
The patent includes treatment method claims that convert formulation presence into an activity claim.
- Claim 33: method of treating a human infected with hepatitis C virus by administering the composition of Claim 1
- Claim 34: Claim 33 where composition is administered with ribavirin
- Claim 35: method treating hepatitis C by administering the unit dosage form of Claim 17
- Claim 36: Claim 35 with administration with ribavirin
- Claim 37: Claim 36 “as part of an interferon-free treatment regimen”
Key scope point: the method claims inherit the crystalline XRPD and dosage-form requirements of their referenced composition/unit claims. If an accused product avoids the claimed crystalline form, it can be outside method-claim coverage.
Claim-by-claim scope map (what you must match to infringe)
| Claim |
What must be present |
Where infringement is most likely to be proved |
| 1 |
Composition; crystalline GS-7977; XRPD peaks about 6.1 & 12.7; 25–35% w/w loading; excipient |
XRPD testing + assay for % API in final blend |
| 2 |
Claim 1 plus expanded XRPD list (14+ peaks incl. 8.2, 10.4, 17.2…23.3) |
XRPD peak match using accused product solid form |
| 3-12 |
Excipient class selections; optional coating agent |
Formulation composition + excipient ID |
| 4-11 |
Specific excipient lists; preferred mannitol/MCC; croscarmellose sodium; colloidal silica; Mg stearate |
Analytical excipient roster and typical formulation recipes |
| 13 |
Specific excipient proportion windows by % w/w |
Blend composition ratios |
| 14-15 |
Exact exemplar composition weights (including 33% API in Claim 15) |
Exact recipe match |
| 16 |
Unit dosage form; 400 mg GS-7977; XRPD anchor peaks; excipient |
Drug content uniformity + XRPD |
| 17 |
Claim 16 plus expanded XRPD list |
XRPD match |
| 18-26 |
Same excipient class/list logic as Claims 3-11 but in unit-dose context |
Excipient ID and mg quantities |
| 27-30 |
Optional coating; capsule/tablet |
Dosage form type |
| 28 |
Unit excipient mg ranges (diluent/disintegrant/glidant/lubricant) |
Tablet/capsule content + excipient mg targets |
| 29 |
Exact unit-dose exemplar mg recipe |
Full recipe match |
| 31 |
Specific process: intragranular + extragranular blending and compression; option coat |
Manufacturing method evidence |
| 32 |
Tablet composition made via Claim 31 |
Process provenance of product |
| 33-37 |
Administering claimed composition/unit for HCV; ribavirin; interferon-free |
Labeling, prescription instructions, and regimen context; also predicate claim coverage |
How does XRPD define the patent boundary, and how can that drive generic risk?
This patent uses a common solid-form enforcement pattern: “crystalline GS-7977” is tethered to XRPD 2θ reflections.
Practical claim boundary created by XRPD anchor peaks
- Minimum XRPD requirement in independent claims:
- 2θ peaks at about 6.1 and 12.7
- Dependent claims broaden the peak signature:
- additional peaks at 8.2, 10.4, 17.2, 17.7, 18.0, 18.8, 19.4, 19.8, 20.1, 20.8, 21.8, and 23.3
Where generic applicants typically lose
- If the accused crystalline form matches the claimed XRPD profile (even via polymorph/isomorph conversion) the “form” limitation is met.
- If API loading and excipient system match typical direct-compression or granulation blends, the rest of the claim reads broadly.
Where design-around can work
- Changing the solid form so the XRPD pattern fails to match the claimed anchors (6.1, 12.7) and/or the expanded peak set can avoid coverage even if the rest of the formulation is the same.
- Shifting excipient ratios outside Claim 13’s windows or moving away from the specified 400 mg unit dose could also reduce claim coverage, depending on which claims are asserted.
What patent landscape surrounds US 8,889,159 for GS-7977?
A complete landscape requires the broader portfolio: earlier compound-form patents for GS-7977 crystallinity and later formulation/process patents for tablet/capsule dosage. The provided prompt supplies only the claim text for 8,889,159, not the full family, prosecution history, or the related patents/continuations in the US.
No complete landscape can be generated from the claim text alone without risking fabrication of other patent numbers, expiration dates, and Orange Book listings.
Which claim elements are most important for licensing and litigation strategy?
1) Crystalline form proof (XRPD)
The strongest contest point is whether the accused product uses the claimed crystalline GS-7977 solid form.
2) Composition arithmetic (w/w API loading and excipient windows)
- Claim 1 API loading: 25% to 35% w/w
- Claim 13 excipient percentage windows are numerical traps.
- Claim 14 and 15 are closer-to-the-recipe exemplars.
3) Unit-dose matching (400 mg)
- Claim 16 requires about 400 mg API per unit dosage form.
- Claim 28 provides excipient mg windows for that unit.
4) Process linkage in tablet manufacturing
- Claim 31 can create an additional infringement theory even if the final composition is argued to be equivalent, if manufacturing steps follow intragranular/extragranular blending and compression.
5) Method claims depend on the predicate composition/unit claims
Claims 33-37 are enforcement multipliers, not independent “clinical efficacy” claims. They typically travel only if the accused product practices Claim 1/16/17.
Key Takeaways
- US 8,889,159 protects crystalline GS-7977-based compositions and unit dosage forms defined by XRPD anchor peaks at about 6.1 and 12.7, with dependent claims adding an expanded XRPD signature.
- Enforcement coverage is driven by solid form identity (XRPD) plus formulation math: API loading (25–35% w/w in composition) and excipient systems (named diluents/disintegrants/glidants/lubricants) with additional proportional constraints in Claim 13 and exemplar recipes in Claims 14-15.
- The patent narrows further to a 400 mg unit format and specific excipient mg ranges, with optional coatings and explicit capsule or tablet coverage.
- A process claim (Claim 31) ties tablet manufacture to intragranular + extragranular blending followed by compression, creating a manufacturing-method enforcement route.
- HCV treatment claims (Claims 33-37) expand reach through administration of the claimed composition/unit, including ribavirin combination and interferon-free regimen language, but they inherit the predicate composition/form limitations.
FAQs
1) Does US 8,889,159 require the full XRPD peak list to be infringed?
No. Independent claims require only the anchor XRPD peaks (about 6.1 and 12.7). The full peak list appears in dependent claims.
2) Can a different excipient set avoid infringement under Claim 1?
If the excipient selection stays within the claimed categories and named lists, excipient substitution is limited. Avoidance is more plausible by changing the crystalline form (XRPD) or moving outside the numerical excipient windows in dependent claims.
3) Is the 400 mg GS-7977 dose required for all claims?
No. The 400 mg unit dosage requirement applies to the unit dosage form claims (including Claims 16 and 17). The broader composition claims require w/w loading rather than a unit mg target.
4) How does the intragranular/extragranular process affect generic launch risk?
If an accused tablet is made by a non-intragranular/extragranular workflow, Claim 31 may be avoidable, though product-form claims could still be asserted if the final composition and XRPD solid form match.
5) Are the interferon-free and ribavirin details enforceable on their own?
They are embedded in the method claims that depend on administration of the claimed composition/unit. If predicate claim coverage fails, the regimen-specific language does not create independent coverage.
References
- United States Patent 8,889,159. (Claims as provided in prompt).
More… ↓
⤷ Start Trial
|
